Sonnet BioTherapeutics - SONN Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sonnet BioTherapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SONN shares.
View SONN analyst ratings or view top-rated stocks.

2 equities research analysts have issued 1 year target prices for Sonnet BioTherapeutics' shares. Their SONN share price forecasts range from $6.70 to $22.00. On average, they expect the company's stock price to reach $14.35 in the next year. This suggests a possible upside of 2,348.8% from the stock's current price.
View analysts price targets for SONN or view top-rated stocks among Wall Street analysts.

Sonnet BioTherapeutics' stock was trading at $1.15 at the start of the year. Since then, SONN shares have decreased by 49.0% and is now trading at $0.5860.
View the best growth stocks for 2023 here.

Sonnet BioTherapeutics saw a decline in short interest in the month of February. As of February 28th, there was short interest totaling 372,200 shares, a decline of 30.7% from the February 13th total of 536,700 shares. Based on an average trading volume of 487,000 shares, the short-interest ratio is currently 0.8 days. Currently, 1.9% of the company's stock are short sold.
View Sonnet BioTherapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our SONN earnings forecast.

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) issued its earnings results on Monday, February, 13th. The company reported ($0.80) earnings per share for the quarter, beating analysts' consensus estimates of ($1.10) by $0.30. The company had revenue of $0.04 million for the quarter. Sonnet BioTherapeutics had a negative trailing twelve-month return on equity of 3,609.07% and a negative net margin of 11,316.93%.

Sonnet BioTherapeutics's stock reverse split on Monday, September 19th 2022. The 1-14 reverse split was announced on Monday, September 19th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Sonnet BioTherapeutics investors own include Gevo (GEVO), Sorrento Therapeutics (SRNE), Boxlight (BOXL), T2 Biosystems (TTOO), Biocept (BIOC), iBio (IBIO), Trevena (TRVN), Vaxart (VXRT), ADMA Biologics (ADMA) and Advanced Micro Devices (AMD).

Sonnet BioTherapeutics trades on the NASDAQ under the ticker symbol "SONN."

Sonnet BioTherapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Geode Capital Management LLC (0.34%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Albert D Dyrness, Pankaj Mohan and Richard T Kenney.
View institutional ownership trends.

Shares of SONN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SONN stock can currently be purchased for approximately $0.59.

Sonnet BioTherapeutics (NASDAQ:SONN) has a market capitalization of $11.85 million and generates $350,000.00 in revenue each year.

Sonnet BioTherapeutics' mailing address is 100 OVERLOOK CENTER SUITE 102, PRINCETON NJ, 08540. The official website for the company is www.chanticleerholdings.com. The company can be reached via phone at 609-375-2227, via email at ir@chanticleerholdings.com, or via fax at 704-366-2463.